menu search

Eur/usd now expected to navigate the 1.0800-1.0930 range – uob

In the opinion of Markets Strategist Quek Ser Leang and Senior FX Strategist Peter Chia at UOB Group, EUR/USD appears to have now embarked on a consol...

January 31, 2023, 6:44 am

Immunome: clinical data with a covid therapeutic and the abbvie collaboration

Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the compan...

January 31, 2023, 2:48 am

Lucid stock enters new phase following buy out rumors: what's going on?

Lucid Group, Inc LCID was falling more than 6% on Monday after surging almost 100% at one point on Friday before settling up 43%....

January 30, 2023, 12:49 pm

Ford and general motors enter a new phase of uncertainty on prices and demand

Ford and General Motors are set to report earnings this week....

January 30, 2023, 12:40 pm

Approval for anavex's blarcamesine looks inevitable after biogen's leqembi approved

FDA grants emergency approval of Biogen/Eisai's Leqembi (previously Lecanemab), based solely on phase 2...

January 30, 2023, 12:13 pm

C4 therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating cft1946, an orally bioavailable bidac™ degrader, in braf v600 mutant solid tumors

WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated ...

January 30, 2023, 12:00 pm

Enphase (enph) and enerix team up for expansion in europe

Enphase's (ENPH) partnership with Enerix expands the former's footprint in the European region....

January 30, 2023, 9:47 am

Fsd pharma says recruiting underway in phase 2 trial of fsd201 for treating chronic pain associated with idiopathic mcas

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the phase 2 clinical trial of ...

January 30, 2023, 9:09 am

Usd/jpy is seen navigating within a range bound theme – uob

USD/JPY is now expected to embark on a consolidative phase in the next weeks, likely within the 128.00-...

January 30, 2023, 8:59 am

How ibd's surveys created the 2023 best online broker list

By using a two-phase survey, investors do an online broker comparison to rank top brokers using 18 key ...

January 30, 2023, 7:00 am

Oncternal therapeutics: making progress and still in buy territory

As ONCT's MCL phase 2 study continues to mature, the data also continues to improve.  In fact, the dat...

January 30, 2023, 5:11 am

Gossamer: disappointing phase 2 results but too cheap to ignore

Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. S...

January 30, 2023, 4:48 am

1 underrated growth stock down 48% to buy in 2023

This industry leader is gearing up for its next big growth phase....

January 29, 2023, 7:30 am

Aerovate: developing an exciting pah drug, initiating with a buy

Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's ph...

January 29, 2023, 7:12 am

Achieve life sciences: all eyes on phase 3 data for smoking cessation drug

ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement ...

January 28, 2023, 11:45 pm

John hammer named ceo of spectrum automotive holdings corp.

New CEO Brings Extensive Industry Experience to Drive Next phase of Growth FAIRFIELD, N.J., Jan. 27, 20...

January 27, 2023, 9:31 pm

Anebulo: interesting drug for cannabis intoxication, but the market potential remains unclear

Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2...

January 27, 2023, 3:49 pm

Could this be novartis' next blockbuster medicine?

The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug...

January 27, 2023, 8:45 am

Dupixent® (dupilumab) recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis

If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a ...

January 27, 2023, 5:59 am

Pxe: positioned for next phase of energy sector bull market

PXE is a quant strategy-based ETF that invests across oil & gas stocks. The fund has impressively outperformed industry benchmarks in recent years....

January 26, 2023, 9:06 pm


Search within

Pages Search Results: